Disclosure and conflict of interest: The authors declare no conflict of interest and no disclosure of information associated with this manuscript.
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis
Article first published online: 30 JUL 2012
Wiley Periodicals, Inc.
Volume 13, Issue 9, pages 1121–1130, September 2012
How to Cite
Gatti, A., Lazzari, M., Gianfelice, V., Di Paolo, A., Sabato, E. and Sabato, A. F. (2012), Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Pain Medicine, 13: 1121–1130. doi: 10.1111/j.1526-4637.2012.01432.x
- Issue published online: 13 SEP 2012
- Article first published online: 30 JUL 2012
- Chronic Pain;
- Pain Management;
- Immune Cells
Objective. To assess the efficacy and safety of palmitoylethanolamide (PEA), an endogenous fatty acid amide belonging to the N-acylethanolamines family, in reducing pain severity in patients with pain associated to different pathological conditions.
Methods. This was an observational study conducted on 610 patients who were unable to effectively control chronic pain with standard therapies. PEA (600 mg) was administered twice daily for 3 weeks followed by single daily dosing for 4 weeks, in addition to standard analgesic therapies or as single therapy. The primary outcome measure was the mean score pain severity evaluated by the numeric rating scale. Safety was also evaluated.
Results. PEA treatment significantly decreased the mean score pain intensity evaluated in all patients who completed the study. The PEA effect was independent of the pain associated pathological condition. PEA-induced decrease of pain intensity was present also in patients without concomitant analgesic therapy. Importantly, PEA showed no adverse effects.
Conclusions. In this study, PEA was effective and safe in the management of chronic pain in different pathological conditions.